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Background/aim: Invasive fungal infection (IFI) causes morbidity and mortality among patients with hematological malignancies. We
evaluated the incidence and treatment characteristics of IFIs between October 2012 and December 2013.
Materials and methods: Patients who received chemotherapy or stem cell transplantation were retrospectively evaluated. Fungal
infections were classified according to EORTC criteria.
Results: Prophylaxis and antifungal therapy were given in 30.5% and 23.6% of 522 chemotherapy courses, respectively. The incidence of
proven/probable IFI was 6.7%. The incidence of IFI among patients who received prophylaxis was significantly higher than among those
who did not receive it (11.3% vs. 4.6%, P = 0.005). There was no significant difference between patients who received mold-active and
no mold-active prophylaxis (P = 0.098). The most common single agent therapy and causative pathogen was liposomal amphotericin B
(57.1%) and Aspergillus (n = 5), respectively. IFI-attributable mortality rate was 14.2% in 6 weeks.
Conclusion: The IFI incidence and mortality rate were similar to that reported in the literature. The IFI rate was higher in the group
using prophylaxis, as this is a high-risk group. Although the IFI rate was not significantly different between groups using prophylaxis,
patients should be followed closely for the effective use of posaconazole prophylaxis.
Key words: Invasive fungal infection, treatment, prophylaxis, hematological malignancies, epidemiology

1. Introduction
Invasive fungal infection (IFI) causes morbidity and
mortality among patients with hematological malignancies
who receive chemotherapy or hematopoietic stem cell
transplantation (HSCT). The incidence of IFI has increased
worldwide over the last two decades (1–3). Prolonged
neutropenia, HSCT, and underlying disease, particularly
acute leukemia, have been identified as risk factors
for IFI (4–6). In recent years, epidemiological studies
have revealed that the incidence of candidiasis has been
decreasing, whereas the incidence of aspergillosis has been
increasing (2,3,6,7). Using novel agents, the development of
diagnostic methods and early administration of antifungal
therapy has improved the management of IFIs (8).
Many studies have investigated the incidence and
treatment outcomes of IFIs in selected hematological
malignancies or treatment modalities (8–10). The first
purpose of this study was to evaluate the incidence of
IFIs in patients receiving chemotherapy for hematological
malignancies. The second purpose of the study was to
* Correspondence: drakadnur@yahoo.com

determine the epidemiology, antifungal prophylaxis,
and antifungal prescriptions of IFIs and the treatment
outcomes of proven and probable IFIs in our cohort at a
Turkish university hospital.
2. Materials and methods
Our hematology unit contains 7 conventional single
rooms, 6 single rooms with HEPA filtration and positive
pressure isolation, and 30 conventional double rooms.
We conducted this monocentric and retrospective study
to describe our fungal infection and antifungal treatment
status. All hospitalized patients with hematological
malignancies who received chemotherapy or HSCT
between 1 October 2012 and 31 December 2013 were
included this study. Patient diagnosis, treatment phase,
clinical signs, imaging and microbiological results,
prophylaxis, antifungal treatment, treatment outcomes,
and reasons for changing the therapy were recorded.
IFIs were classified according to EORTC criteria
as possible, probable, and proven (11). Basically, these
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criteria demand clinical features in combination with
host factors for a possible diagnosis. Probable IFI requires
the presence of host factors, clinical features, and certain
microbiological criteria (e.g., serum galactomannan),
whereas a proven diagnosis demands histopathological
findings or positive culture from a primary sterile site in
combination with host factors and clinical features. In the
case of proven or probable IFI, microbiological evidence
was produced by bronchoscopy, blood culturing, and
histology after biopsy. For patients meeting the criteria
of proven IFI, data on fungal species, organs involved,
method of fungal identification, treatment results, and
6-week survival were recorded.
Galactomannan (GM) testing was performed twice
a week during hospitalization. GM test results with an
optical density index (ODI) of ≥0.5 are considered positive
at our center. These results were obtained over a period of
7 days.
Complete response was defined as the resolution of all
signs of IFI, and partial response was defined as clinical and
radiological improvement or resolution of all attributable
symptoms and signs of fungal disease. Radiological
stabilization can be equated with a partial response. Stable
response was defined as minor or no improvement in

signs of disease and radiological stabilization, whereas
progressive disease was defined as worsening clinical
symptoms or signs of disease and new sites of disease or
radiological worsening of preexisting lesions (12).
As this was an observational study, diagnosis and
treatment practices were determined by treating physicians
according to routine hospital practice. Empirical antifungal
therapy was administered to patients with persistent
neutropenic fever, whereas preemptive antifungal therapy
was administered to those whose clinical or radiological
findings were suggestive of IFIs.
2.1. Statistical analysis
Quantitative variables were described as the number and
percentage while qualitative variables were the median
and range. Statistical analysis was performed using the
chi-square test, Fisher’s exact test, or t-test as appropriate
using SPSS 20.4 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Patient characteristics
We evaluated 416 patients receiving 522 chemotherapy
courses. The demographics and clinical characteristics of
the patients are shown in Table 1. The median age of the 416

Table 1. Demographics and clinical characteristics of patients (n = 416) treated with chemotherapy (n = 522) for hematological
malignancies.
Patients characteristics

All patients (n = 416)

All chemotherapy courses (n = 522)

Median age (min–max)

57 (17–89)

57 (17–89)

Male/female (%)

259/157 (62.2/37.8)

320/202 (61.3/38.7)

Diagnoses (%)
Acute leukemia
Myelodysplastic syndrome
Lymphoma
Myeloma
Chronic leukemia
Myelofibrosis with myeloid metaplasia

93 (22.3)
30 (7.3)
148 (35.6)
110 (26.4)
32 (7.7)
3 (0.7)

124 (23.8)
35 (6.7)
186 (35.6)
137 (26.2)
37 (7.1)
3 (0.6)

Treatment phase (%)
Remission induction
Postremission treatment
Relapse or refractory disease treatment
Transplantation (allo/auto)

169 (40.6)
118 (28.4)
49 (11.8)
80 (19.2)

176 (33.7)
176 (33.7)
62 (11.9)
108 (20.7)

Previous IFI (n, %)

4 (0.9)

6 (1.1)

Antifungal prophylaxis, yes (%)

122 (29.3)

159 (30.5)

Mold-active

48 (11.5)

60 (11.4)

No mold-active

74 (17.8)

99 (19)

Allo: Allogeneic, auto: autologous, CR: complete remission, PR: partial remission.
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patients was 57 years (17–89 years), and 62.2% of patients
were male. The underlying diseases in the patients were
acute leukemia (22.3%), lymphoma (35.6%), plasma cell
disorders (26.4%), and other hematological malignancies
(15.7%). The most common chemotherapy phase was
remission induction (40.6%). Previous IFI history was
obtained from 4 (1%) of the patients.
3.2. IFI prophylaxis
Prophylaxis was used in 159 (30.5%) of 522 chemotherapy
courses. In 6 (1.1%) of 522 chemotherapy courses,
voriconazole was used for secondary prophylaxis. In
54 (10.3%) and 99 (19%) of 522 chemotherapy courses,
posaconazole and fluconazole were given for primary
prophylaxis, respectively. The most common reasons
for prophylaxis were transplantation (n = 108, 68%) and
remission induction chemotherapy (n = 36, 22.6%).

All
patients
who
underwent
autologous
transplantations (n = 70) received fluconazole prophylaxis.
In 23 and 14 of 38 patients who underwent allogeneic
transplantations, fluconazole and posaconazole were
used for prophylaxis, respectively. One patient received
voriconazole prophylaxis.
3.3. Incidence of IFI
Among the 522 chemotherapy courses, 9 (1.7%) were
diagnosed as having proven IFI, 26 (5%) as probable IFI,
and 29 (5.6%) as possible IFI, while 59 (11.3%) failed to
meet the EORTC diagnostic criteria. The incidence of
proven/probable IFI was 6.7%. The mean age of the patients
diagnosed with proven/probable IFI and not with IFI was
55.49 ± 12.51 and 58.31 ± 15.019 years, respectively (P =
0.27). Their sex, underlying disease, treatment phase, and
antifungal prophylaxis are shown in Table 2.

Table 2. Incidence of IFIs in patients treated with chemotherapy (n = 522) for hematological malignancies and antifungal therapies.
Patient characteristics

All courses

Number of IFI cases (n)

Incidence of IFI (%)

All chemotherapy

522

35

6.7

Male

320

28

8.8

Female

202

7

3.4

Acute leukemia

124

21

16.9

AML

101

17

16.8

ALL

23

4

17.4

Myelodysplastic syndrome

35

2

5.7

Lymphoma

186

5

2.7

Myeloma

137

4

3

Chronic leukemia

37

3

8.1

MMM

3

0

0

Remission induction

176

11

6.3

Postremission treatment

176

4

2.3

Relapse or refractory disease treatment

62

10

16.1

HSCT (allo/auto)

108

10

9.3

Yes

159

18

11.3

Mold-active

60

10

16.6

No mold-active (fluconazole)

99

8

8

No

363

17

4.6

Sex

Diagnoses

Treatment phase

Antifungal prophylaxis

Allo: Allogeneic, auto: autologous, AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, MMM: myelofibrosis with
myeloid metaplasia, CR: complete remission, PR: partial remission.
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Compared to the overall population, the incidence of
IFI was higher among patients with acute leukemia (n =
21, 16.9%, P = 0.000), those in relapse/refractory treatment
phase (n = 10, 16.1%, P = 0.001), and those receiving
antifungal prophylaxis (n = 18, 11.3%, P = 0.005). The risk
of developing IFI was greater in males (n = 28, 8.8%, P =
0.019). The antifungal agents used in proven/probable IFIs
were liposomal amphotericin B (LAmpB) (n = 20, 57.1%),
caspofungin (n = 5, 14.3%), voriconazole (n = 9, 25.7%),
and amphotericin B deoxycholate (AmpB) (n = 1, 2.9%).
Only 2 patients were treated with a combination of two
antifungal agents. One of these patients was treated with
LAmpB and caspofungin for probable IFI, and the other
was treated with voriconazole and LAmpB for proven IFI.
The incidence of proven/probable IFI was 11.3% in
159 chemotherapy courses using prophylaxis. Proven
and probable IFIs were diagnosed in 10 (16.6%) of 60
chemotherapy courses that used mold-active prophylaxis
[posaconazole (15%) and voriconazole (1.6%)] and in
8 (8%) of 99 chemotherapy courses that did not use any
mold-active prophylaxis. The risk of developing IFI was
similar among those receiving mold-active prophylaxis
and those not receiving it (P = 0.098). One patient who
received secondary prophylaxis with voriconazole was
diagnosed with mucormycosis. The median time from
neutropenia to the diagnosis of proven/probable IFI was 7
days (range: 1–40), the median treatment duration was 24
days (range: 5–77), and the median neutrophil count was
56/mm3 (range: 0–10600).
Among the 108 patients who underwent HSCT (38
allogeneic HSCT recipients and 70 autologous HSCT
recipients), proven/probable IFIs occurred in 10 patients
(overall incidence: 9.2%). IFI-attributable mortality
was 0.9% (n = 1). Of 10 patients, 6 received fluconazole
prophylaxis and 4 received posaconazole prophylaxis.
3.4. Antifungal therapy
Systemic antifungal agents were used in 123 (23.6%) of 522
chemotherapy courses. The median time from neutropenia
to first administration of antifungal agents was 6 days
(range: 1–40), the median neutrophil count was 30/mm3
(range: 0–10600), and the median treatment duration was
15 days (range: 1–77) in patients who received antifungal
treatment. Prophylaxis was given to 71 of 123 (57.7%)
chemotherapy courses that used systemic antifungal
agents. There were 32 (26%) courses using fluconazole, 37
(30%) courses using posaconazole, and 2 (1.7%) courses
using voriconazole. Among those using antifungal therapy,
the most common underlying disease was acute leukemia
(n = 69, 57%), and the most common therapy phases were
remission induction (n = 44, 35.8%) and transplantation
(n = 38, 30.9%).
The used antifungal agents were LAmpB (n = 68,
55.3%), caspofungin (n = 25, 20.3%), voriconazole (n = 15,
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12.2%), and AmpB (n = 15, 12.2%). In 56 (45.5%) of the
123 patients, the first antifungal agent was changed into
another. The reasons for changing were lack of efficacy
(n = 28, 50%), adverse event (n = 22, 39.3%), and drug–
drug interactions (n = 6, 10.7%). The antifungal therapy
approach was preemptive in 11 (9%) and empirical in 112
(91%) chemotherapy courses.
3.5. Patient characteristics with proven and probable IFIs
Among proven and probable IFI cases, the most common
underlying disease was acute leukemia (n = 21) and the
most common therapy phases were remission induction
(n = 11) and transplantation (n = 10). Twenty-six patients
were diagnosed with probable pulmonary aspergillosis, as
determined by computed tomography scan and positive
GM assay.
In 9 patients with proven IFI, Candida (n = 2),
Mucor (n = 2), and Aspergillus (n = 5) were the causative
pathogens. The sites of infection among patients with
proven Aspergillosis were lung (n = 2), nasal sinus (n =
1), and both lung and nasal sinus (n = 2). Samples were
obtained from nasal sinus biopsy and bronchoalveolar
lavage fluid. Two patients were diagnosed with candidemia
and positive blood cultures. Patients with mucormycosis
(n = 2) were identified with nasal sinus biopsies. The
demographics and clinical characteristics of patients with
proven IFIs are shown in Table 3. The incidence of invasive
aspergillosis was 5.9%, the incidence of candidiasis was
0.4%, and the incidence of mucormycosis was 0.4% among
the 522 chemotherapy courses.
3.6. Mortality
Five (14.2%) of 35 patients with proven (3 patients) and
probable (2 patients) IFIs died within 6 weeks as a result
of progressive IFI. Two of the 5 deaths in patients with
proven/probable IFI were newly diagnosed patients who
had received induction chemotherapy; one was in relapsed
disease; one was in partial remission; and one was in
complete remission.
4. Discussion
IFI is a prominent cause of morbidity and mortality
in patients with hematological malignancies and
HSCT recipients. In this retrospective study, we report
the outcomes of real-life experience in patients with
hematological malignancies followed and treated at our
clinic.
First, the results indicated that the incidence of
probable/proven IFI (6.7%) and 6-week IFI-attributable
mortality (14.2%) were compatible with other studies. In
the SEIFEM-2004 study, the incidence of IFI was reported
as 4.6%, and IFI-attributable mortality rate was 39%, which
is slightly higher than ours (6). Another study reported the
incidence of probable/proven IFI as 8.5% (13). In a French
study, the incidence of IFI was found to be 2.1%, and no
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Table 3. Demographics and clinical characteristics of patients (n = 9) with proven IFI treated with chemotherapy (n = 522) for
hematological malignancies.
Age, sex

Diagnosis

Prophylaxis

Treatment phase

Antifungal therapy

Outcome

Species

68, M

CLL

No

Consolidation

LAmpB/ Caspo

Death/PD

Candida spp.

51, M

MM

Posa

Transplant

LAmpB/ Vori

CR

Aspergillus fumigatus

52, M

AML

Vori

Reinduction

LAmpB

CR

Mucor

56, F

AML

Flu

Transplant

LAmpB+ Vorico

CR

Aspergillus spp.

66, M

NHL

Flu

Transplant

LAmpB/ Caspo

PR

Candida spp.

43, F

AML

Posa

Transplant

LAmpB

Death/PD

Aspergillus fumigatus

63, M

CLL

No

Consolidation

LAmpB/ Vori

CR

Aspergillus spp.

46, M

ALL

Posa

Transplant

Caspo/LAmpB

PR

Mucor

68, M

MDS

No

Remission induction

LAmpB/ Vori

Death/PD

Aspergillus flavus

LAmpB: Liposomal amphotericin B, vori: voriconazole, caspo: caspofungin, posa: posaconazole, flu: fluconazole, PD: progressive
disease, CR: complete remission, PR: partial remission.

death was attributed to it (7). According to the available
postmortem data, the prevalence of IFIs at autopsy was
determined as 6.6% in 1993–1996 and 10.4% in 2001–2005
(14). In a Japanese study, incidence of IFI was 1.3%, but
IFI-attributable mortality was 36.8% (15). In the CAESAR
study, incidence of IFI was 2.1% per chemotherapy course
and mortality rate was 11.7% in the proven/probable IFI
(16). These outcomes indicate that mortality rates remain
high, although the incidence of IFI has declined in the past
decade due to improved preventive strategies.
The rate of systemic antifungal usage was 23.6% in our
study. Compared to the literature, systemic antifungal usage
was higher than in other studies (13.4%–17%) (7,13,16). This
may be mainly related to diagnostic explication differences
and local clinical conditions. It is slightly probable that the
prepossession of the radiologist might lead to interpreting
the diagnosis as IFI, or our GM assays might occasionally
conflict due to technical problems or patient-related
conditions such as widespread use of penicillin-based
antibiotherapy. The distribution of underlying diseases
and treatment phases was similar to that of other studies;
acute leukemia was the most common diagnosis (57%) and
remission induction and transplantation were the most
common treatment phases (35.8% and 30.9%, respectively)
(7,13). In our study, the most commonly used antifungal
agent was LAmpB (55.3%), and the most common reason
for changing was lack of efficacy (50%). These findings are
similar to other studies in the literature (16). According
to this evaluation, the frequency and cost of antifungal
treatment during the induction phase of patients with acute
leukemia and in the process of HSCT is still conspicuously
high and poses a serious problem.

Aspergillus spp. was the most common causative agent
in probable/proven IFI, supporting the previously reported
data (17). The incidence of aspergillosis was 5.9%, which
was slightly higher than that declared in other studies
(0.8%–2.6%) (6,7,15). The environmental conditions of
our clinic might have led to increased IFI rates, as longterm refurbishment studies might have exacerbated moldrelated fungal infections. Additionally, host factors, such as
personal hygiene and isolation rules, should be considered.
The lung was the most common involvement site in other
data, as well. The incidence of candidiasis was 0.4%, which
was consistent with other studies (0.2%–10%) (3,6,7,15).
Remarkable morbidity and mortality rates related to
IFIs emphasize the importance of prophylactic antifungal
treatment regimens for high-risk patients (18). Focusing
on the patient group that received antifungal therapy (n
= 123), we noticed that the prophylaxis rate was 57.7%.
These data were slightly higher than those reported in the
literature, where the prophylaxis rate has been reported as
41.7%–44% (7,13,19). The main reason for the high rate
of prophylaxis might be related to patient characteristics.
Among the 123 chemotherapy courses in which AF
prophylaxis was used, 38 (30.9%) were autologous or
allogeneic HSCT.
Although the proven/probable IFI rate was two-fold
higher in the group using mold-active prophylaxis (16.6%
vs. 8%), this difference was not statistically significant. In a
study from Spain, proven/probable IFI rates were 47% and
47.3% in patients who received mold-active prophylaxis
and no mold-active prophylaxis, respectively (20). In
another study from France, the probable IFI rate was 11.4%
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in patients who received posaconazole prophylaxis. The
authors concluded that the posaconazole oral suspension
administration did not decrease the incidence of IFI. They
also concluded that these findings were associated with
interruptions of prophylactic treatment due to mucositis,
concomitant use of PPIs, poor absorbers, and diarrhea
(21). All causes mentioned above might be associated with
two-fold higher IFI rate in our study.
In this study, the prevalence of proven/probable IFI
among patients who received antifungal prophylaxis
was significantly higher than among patients who did
not receive prophylaxis (11.3% vs. 4.6%). The higher
prevalence of IFIs among patients who received antifungal
prophylaxis might be attributed to patient characteristics,
interruptions of prophylactic treatment, unpredictable
bioavailability of AF agents used for prophylaxis, and
breakthrough IFI (bIFI). It should be noted that the patients
who received prophylaxis were in a high-risk group. In
this study, the most common causes of prophylaxis were
transplantation and remission induction chemotherapy.
The rate of high-risk patients for IFI who received
prophylaxis, except autologous transplantation, was
46.5%. As mentioned above, interruptions of prophylactic
treatment due to mucositis might be associated with a high
IFI rate. Another explanation for high IFI incidence may
be the unpredictable or sometimes poor bioavailability
of antifungal agents (especially posaconazole) used for
prophylaxis. In the literature, observational studies on
bIFI have reported incidences of probable/proven bIFI
ranging from 3% to 13% (22–28). The rate of bIFI observed
in the group receiving prophylaxis is compatible with the
literature.
The frequencies of posaconazole, fluconazole, and
voriconazole usage were found to be 15%, 8%, and 1.6%,
respectively. In an observational prospective French study,
antifungal prophylaxis was found to be used in 56% of the
proven IFIs, and the distribution of prophylactic agents in
proven cases was 59.3% fluconazole, 18.5% ampB, 6.2%
voriconazole, and 6.2% posaconazole (19). In a prospective
epidemiologic study from Austria, the proven/probable IFI
rate was 8.5% in patients who received antifungal therapy
and there was a different distribution of prophylactic
agents: 63.5% of prescriptions were posaconazole, 25%

were itraconazole, and 11.5% were fluconazole. The
authors suggested that the low rate of IFI correlated with
the extensive use of posaconazole (13). Thus, different
approaches in prophylaxis may alter the outcomes and
provide information about effective preventive strategies.
Moreover, ECIL-4 guidelines emphasize the importance
of local epidemiology in designing an appropriate
institutional prophylaxis strategy (29).
In our study, an empirical approach was used in
91% of chemotherapy courses in which antifungal
therapy was given. Although there were encouraging
data supporting preemptive treatment, subsequent
clinical trials indicated that the empirical approach is
still the standard of care for neutropenic patients with
hematological malignancies, especially in the high-risk
group (8,30–32). LAmpB was the most commonly used
antifungal therapy in our study (57.1%). Turkish expert
opinion (TEO) articles reported that conventional AmpB
is still included in the recommendations of the Turkish
Healthcare Implementation Notification for first-line
antifungal treatment, although it is not recommended
in the guidelines. In TEO, the authors concluded that,
especially in high-risk patients, an empirical approach and
modification of treatment when required according to the
diagnostic outcomes would be more reliable and valid for
Turkey (33).
In conclusion, the incidences of IFIs and IFIattributable mortality were compatible with the literature.
The proven/probable IFI rate was higher in those groups
using prophylaxis. However, it should be kept in mind that
the patients who received prophylaxis are a high-risk group.
Although the proven/probable IFI rate was not significantly
different between groups using mold-active and no-mold
active prophylaxis, patients should be followed closely for
the effective use of posaconazole prophylaxis. Improving
environmental conditions and using new formulations of
posaconazole could improve higher proven/probable IFI
rates. Empirical antifungal therapy is still an important
approach to reducing mortality rate.
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